麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

澳大利亞CSL Limited 
總部位于澳大利亞墨爾本市的CSL Limited公司是一家全球化的專業生物制藥公司，致力于研發、生產和銷售以蛋白質為基礎的藥物，以治療和預防嚴重的人類疾病。CSL集團在研發和生產疫苗和血漿蛋白生物治療制劑方面擁有90多年的技術經驗，為醫學與人類健康做出了杰出的貢獻，這是公司的一筆寶貴財富。我們將堅定不移地增加以蛋白質為基礎的生物藥品的研發投入，以滿足那些尚未得到滿足的醫療需求，并將其作為我們繼續成長的根基。

CSL集團包括CSL Bioplasma、以及CSL Behring并購的ZLB Plasma公司。CSL的主要生產基地位于澳大利亞、德國、瑞士與美國境內，它在27個國家共雇用了8600多名員工。

The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies.

With major facilities in Australia, Germany, Switzerland and the US, CSL has over 10,000 employees working in 27 countries.

Our Areas of Expertise

Plasma Products
Human plasma is used to produce a wide range of life-saving medicines.

Our various businesses support all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma-derived products.

The key businesses involved with plasma products include:

CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through CSL Plasma

CSL Bioplasma is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. We also manufacture and market in vitro diagnostic products through Immunohaematology

Vaccines & Pharmaceuticals
We manufacture and provide influenza vaccine globally.

In Australia and New Zealand, CSL Biotherapies also markets a comprehensive range of vaccines and antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.

Research & Development
Our activities at CSL are focused on new product development, life-cycle management and safety of our extensive product portfolio. CSL invests in the development of protein-based medicines for treating serious human diseases. Medicines can be made from plasma, traditional biological sources or using recombinant biotechnology. More information is available in the Research & Development section.